These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37871779)

  • 21. Neoadjuvant toripalimab plus platinum-paclitaxel chemotherapy in stage II-III non-small cell lung cancer: a single-center, single-arm, phase I study in China.
    Hou H; Wang Y; Sun D; Zhu J; Jiang M; Zhang X; Zhou N; Zhang C; Li T; Zhang X
    Invest New Drugs; 2023 Feb; 41(1):86-92. PubMed ID: 36508040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review.
    Zhao Z; Gao Y; Xue Q; Gao S; He J
    Target Oncol; 2021 Jul; 16(4):425-434. PubMed ID: 33983556
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
    Hines JB; Cameron RB; Esposito A; Kim L; Porcu L; Nuccio A; Viscardi G; Ferrara R; Veronesi G; Forde PM; Taube J; Vokes E; Bestvina CM; Dolezal JM; Sacco M; Monteforte M; Cascone T; Garassino MC; Torri V
    J Thorac Oncol; 2024 Jul; 19(7):1108-1116. PubMed ID: 38461929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
    Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
    Zhang R; Zhu J; Liu Y; Xin Y; Wang Y; Niu K; Wei H
    Medicine (Baltimore); 2021 Mar; 100(10):e19713. PubMed ID: 33725808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of perioperative, neoadjuvant, or adjuvant immunotherapy alone or in combination with chemotherapy in early-stage non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials.
    Meng Y; Zhang Q; Wu R; Li H; Wang Z; Yao Y; Li X; Chen Z; Gong Y; Liu H
    Ther Adv Med Oncol; 2024; 16():17588359241284929. PubMed ID: 39376583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trajectory of PD-L1 expression in a patient underwent neoadjuvant chemo-immunotherapy for resectable NSCLC.
    Gallina FT; Balzano V; Porciello N; Tajè R; Forcella D; Melis E; Letizia Cecere F; Fusco F; Buglioni S; Visca P; Nisticò P; Cappuzzo F; Spicer J
    Lung Cancer; 2024 Aug; 194():107900. PubMed ID: 39079181
    [No Abstract]   [Full Text] [Related]  

  • 28. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yi K; Zhu Q; Kuang YK; Jiang SC; Hu H
    Int Immunopharmacol; 2020 Oct; 87():106852. PubMed ID: 32759049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
    Li X; Huang C; Xie X; Wu Z; Tian X; Wu Y; Du X; Shi L
    J Clin Pharm Ther; 2021 Apr; 46(2):256-266. PubMed ID: 33152129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis.
    Fukuda N; Horita N; Namkoong H; Kaneko A; Somekawa K; Tagami Y; Watanabe K; Hara Y; Kobayashi N; Kaneko T
    Thorac Cancer; 2022 Jan; 13(1):84-94. PubMed ID: 34791815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis.
    Masarwy R; Kampel L; Horowitz G; Gutfeld O; Muhanna N
    JAMA Otolaryngol Head Neck Surg; 2021 Oct; 147(10):871-878. PubMed ID: 34473219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y; Luo H; Zheng XL; Ge H
    Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
    Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
    Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis.
    Li B; Gu Y; Zhao W; Li Z; Guo W; Lu X; Jiang J
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39251495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
    Li W; Jiang J; Huang L; Long F
    Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
    Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
    Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.